FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3015113743> ?p ?o ?g. }

• W3015113743 endingPage "536" @default.
• W3015113743 startingPage "536" @default.
• W3015113743 abstract "<h3>Importance</h3> Rates of visual field (VF) progression vary among patients with glaucoma. Knowing the rate of progression of individual patients would allow appropriately aggressive therapy for patients with high rates of visual loss and protect those with low rates from unnecessary therapy. <h3>Objective</h3> To compare 3 pointwise methods of estimating the rate of VF progression in glaucoma. <h3>Design, Setting, and Participants</h3> This retrospective, observational cohort study included 729 eyes of 567 consecutive patients with primary open-angle glaucoma who had at least 6 reliable VFs and at least 3 years of follow-up. One hundred seventy-six patients (257 eyes) were treated at a tertiary glaucoma center; in addition, data were collected from 391 participants (472 eyes) in the Advanced Glaucoma Intervention Study. Data were collected from May 1988 to November 2004 and analyzed from October 2018 to February 2019. <h3>Exposures</h3> Estimates of VF progression were measured with guided progression analysis (GPA), pointwise linear regression (PLR), and the glaucoma rate index (GRI). A subgroup analysis was performed in a subset of patients with likely VF progression and likely VF stability. <h3>Main Outcomes and Measures</h3> Proportion of VF series detected as progressing, estimates of false-positive proportions, time to detect progression, and agreement among measures. <h3>Results</h3> Among the 567 patients included in the analysis, mean (SD) age was 65.6 (9.7) years, 300 (52.9%) were female, and 295 (52.0%) were white. The median baseline mean deviation was −6.7 (interquartile range [IQR], −11.6 to −3.5) dB; the median follow-up time, 8.9 (IQR, 7.3-10.4) years. The proportion of eyes labeled as progressing was 27.7% according to the GPA, 33.5% according to the PLR, and 52.9% according to the GRI; pairwise differences for GRI vs PLR were 20% (95% CI, 17%-23%); for GRI vs GPA, 25% (95% CI, 22%-29%); and for PLR vs GPA, 6% (95% CI, 3%-9%;<i>P</i> < .001 for all comparisons, McNemar test). The shortest median time to progression was with the GRI (8.8 [IQR, 2.4-10.5 years), compared with the GPA and PLR (both >16 years). The hazard ratio of VF progression for GRI vs PLR (reference) was 11.3 (95% CI, 9.2-13.7); for GRI vs GPA (reference), 18.1 (95% CI, 14.5-22.6); and for PLR vs GPA (reference), 1.5 (95% CI, 1.3-1.9;<i>P</i> < .001 for all comparisons, Cox proportional hazards regression). These results held in the subgroup with likely progression; the proportions of progressing eyes were 73.7% (115 of 156) for GPA, 81.4% (127 of 156) for PLR, and 92.9% (145 of 156) for GRI. Pairwise difference for GRI vs PLR was 11.5% (95% CI, 7.4%-17.6%;<i>P</i> < .001, McNemar test); for GRI vs GPA, 19.2% (95% CI, 12.6%-26.4%;<i>P</i> < .001, McNemar test); and for PLR vs GPA, 7.7% (95% CI, 0.3%-15.7%;<i>P</i> = .08, McNemar test). <h3>Conclusions and Relevance</h3> These results suggest GRI can detect long-term VF progression in glaucoma earlier than PLR or GPA. Validation with prospective designs may strengthen the generalizability and value of this method." @default.
• W3015113743 created "2020-04-10" @default.
• W3015113743 creator A5001300858 @default.
• W3015113743 creator A5028984179 @default.
• W3015113743 creator A5029420545 @default.
• W3015113743 creator A5029874503 @default.
• W3015113743 creator A5047319321 @default.
• W3015113743 creator A5056101155 @default.
• W3015113743 creator A5058999490 @default.
• W3015113743 creator A5076786379 @default.
• W3015113743 creator A5085793197 @default.
• W3015113743 date "2020-05-01" @default.
• W3015113743 modified "2023-09-27" @default.
• W3015113743 title "Pointwise Methods to Measure Long-term Visual Field Progression in Glaucoma" @default.
• W3015113743 cites W1768004330 @default.
• W3015113743 cites W1968811682 @default.
• W3015113743 cites W1985531175 @default.
• W3015113743 cites W1999677058 @default.
• W3015113743 cites W2000670481 @default.
• W3015113743 cites W2007611245 @default.
• W3015113743 cites W2013585084 @default.
• W3015113743 cites W2013856826 @default.
• W3015113743 cites W2014388846 @default.
• W3015113743 cites W2014539110 @default.
• W3015113743 cites W2018415881 @default.
• W3015113743 cites W2026209674 @default.
• W3015113743 cites W2035378031 @default.
• W3015113743 cites W2049488378 @default.
• W3015113743 cites W2079302533 @default.
• W3015113743 cites W2090561303 @default.
• W3015113743 cites W2112566344 @default.
• W3015113743 cites W2112577549 @default.
• W3015113743 cites W2123483003 @default.
• W3015113743 cites W2130206051 @default.
• W3015113743 cites W2160605010 @default.
• W3015113743 cites W2162085846 @default.
• W3015113743 cites W2164777277 @default.
• W3015113743 cites W2294768168 @default.
• W3015113743 cites W2318409866 @default.
• W3015113743 cites W2319331509 @default.
• W3015113743 cites W2369882343 @default.
• W3015113743 cites W2412348844 @default.
• W3015113743 cites W2538193133 @default.
• W3015113743 cites W2763112447 @default.
• W3015113743 cites W2889066796 @default.
• W3015113743 cites W2903280335 @default.
• W3015113743 cites W2910439267 @default.
• W3015113743 cites W2912084594 @default.
• W3015113743 cites W2912994190 @default.
• W3015113743 cites W2973105050 @default.
• W3015113743 cites W4242563711 @default.
• W3015113743 cites W4254209618 @default.
• W3015113743 cites W4292528167 @default.
• W3015113743 doi "https://doi.org/10.1001/jamaophthalmol.2020.0647" @default.
• W3015113743 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7118669" @default.
• W3015113743 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32239185" @default.
• W3015113743 hasPublicationYear "2020" @default.
• W3015113743 type Work @default.
• W3015113743 sameAs 3015113743 @default.
• W3015113743 citedByCount "2" @default.
• W3015113743 countsByYear W30151137432022 @default.
• W3015113743 countsByYear W30151137432023 @default.
• W3015113743 crossrefType "journal-article" @default.
• W3015113743 hasAuthorship W3015113743A5001300858 @default.
• W3015113743 hasAuthorship W3015113743A5028984179 @default.
• W3015113743 hasAuthorship W3015113743A5029420545 @default.
• W3015113743 hasAuthorship W3015113743A5029874503 @default.
• W3015113743 hasAuthorship W3015113743A5047319321 @default.
• W3015113743 hasAuthorship W3015113743A5056101155 @default.
• W3015113743 hasAuthorship W3015113743A5058999490 @default.
• W3015113743 hasAuthorship W3015113743A5076786379 @default.
• W3015113743 hasAuthorship W3015113743A5085793197 @default.
• W3015113743 hasBestOaLocation W30151137431 @default.
• W3015113743 hasConcept C118487528 @default.
• W3015113743 hasConcept C119060515 @default.
• W3015113743 hasConcept C126322002 @default.
• W3015113743 hasConcept C167135981 @default.
• W3015113743 hasConcept C2776058522 @default.
• W3015113743 hasConcept C2778527774 @default.
• W3015113743 hasConcept C71924100 @default.
• W3015113743 hasConceptScore W3015113743C118487528 @default.
• W3015113743 hasConceptScore W3015113743C119060515 @default.
• W3015113743 hasConceptScore W3015113743C126322002 @default.
• W3015113743 hasConceptScore W3015113743C167135981 @default.
• W3015113743 hasConceptScore W3015113743C2776058522 @default.
• W3015113743 hasConceptScore W3015113743C2778527774 @default.
• W3015113743 hasConceptScore W3015113743C71924100 @default.
• W3015113743 hasIssue "5" @default.
• W3015113743 hasLocation W30151137431 @default.
• W3015113743 hasLocation W30151137432 @default.
• W3015113743 hasOpenAccess W3015113743 @default.
• W3015113743 hasPrimaryLocation W30151137431 @default.
• W3015113743 hasRelatedWork W1949172687 @default.
• W3015113743 hasRelatedWork W1974277164 @default.
• W3015113743 hasRelatedWork W1987482940 @default.
• W3015113743 hasRelatedWork W2017696393 @default.
• W3015113743 hasRelatedWork W2036518491 @default.
• W3015113743 hasRelatedWork W2090906421 @default.

• next